OpGen

OpGen ROIC

The Return on Invested Capital (ROIC) of OpGen (OPGN) as of Oct 27, 2026 is 70.08 %. In the previous year, Return on Invested Capital (ROIC) was 162.49 % — a change of -56.87% (lower).

ROIC

70.08 %

YoY

-56.87%

Last updated:

Return on Invested Capital (ROIC) of OpGen is 2025 70.08 % . Return on Invested Capital (ROIC) of OpGen was 2024 162.49 % . It decreases by -56.87% lower compared to the previous year.

The OpGen ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
-256.87 USD
Jan 1, 2019
-137.53 USD
Jan 1, 2020
-59.52 USD
Jan 1, 2021
-52.42 USD
Jan 1, 2022
-166.33 USD
Jan 1, 2023
-2,204.20 USD
Jan 1, 2024
162.49 USD
Jan 1, 2025
70.08 USD
The OpGen ROIC history
YEARROICYoY
70.08 %-56.87%
162.49 %-107.37%
-2,204.20 %+1,225.20%
-166.33 %+217.29%
-52.42 %-11.92%
-59.52 %-56.72%
-137.53 %-46.46%
-256.87 %-54.99%
-570.75 %+34.66%
-423.83 %+122.78%
-190.25 %-261.90%
117.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Return on Invested Capital (ROIC) of OpGen is 70.08 % in 2025.

Return on Invested Capital (ROIC) of OpGen changed from 162.49 % to 70.08 %, representing a -56.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) OpGen since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s OpGen with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — OpGen

All Key Metrics — OpGen